scholarly journals Diabetes-induced Changes in Mannan-binding Lectin Levels and Complement Activation in a Mouse Model of Type 1 Diabetes

2013 ◽  
Vol 77 (3) ◽  
pp. 187-194 ◽  
Author(s):  
J. A. Østergaard ◽  
M. Bjerre ◽  
F. Dagnaes-Hansen ◽  
T. K. Hansen ◽  
S. Thiel ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Mouse Model ◽  
Complement Activation ◽  
Induced Changes ◽  
Mannan Binding Lectin ◽  
Binding Lectin

Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes

2017 ◽  
Vol 33 (5) ◽  
pp. e2895 ◽  
Author(s):  
J.A. Østergaard ◽  
S. Thiel ◽  
I.T. Hoffmann-Petersen ◽  
P. Hovind ◽  
H.-H. Parving ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Complement Factor ◽  
Newly Diagnosed ◽  
Mannan Binding Lectin ◽  
Binding Lectin

scholarly journals Elevated Levels of Mannan-Binding Lectin in Patients with Type 1 Diabetes

2003 ◽  
Vol 88 (10) ◽  
pp. 4857-4861 ◽  
Author(s):  
Troels Krarup Hansen ◽  
Steffen Thiel ◽  
Søren Tang Knudsen ◽  
Claus Højbjerg Gravholt ◽  
Jens Sandahl Christiansen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Mannan Binding Lectin ◽  
Binding Lectin

scholarly journals Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Gry Høst Dørflinger ◽  
Charlotte Brink Holt ◽  
Steffen Thiel ◽  
Jakob Appel Østergaard ◽  
Troels Krarup Hansen
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Insulin Pump ◽  
Insulin Dose ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Mannan Binding Lectin ◽  
Improved Glycaemic Control ◽  
Binding Lectin

Objective. Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. Methods. We measured MBL, fructosamine, and HbA1cat baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. Results. After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P<0.0001). There was a significant decrease in HbA1c from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P<0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P<0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P=0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA1c, or fructosamine. Conclusions. MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control.

scholarly journals Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study

Diabetes Care ◽  
2015 ◽  
Vol 38 (10) ◽  
pp. 1898-1903 ◽  
Author(s):  
Jakob A. Østergaard ◽  
Steffen Thiel ◽  
Maria Lajer ◽  
Rudi Steffensen ◽  
Hans-Henrik Parving ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
High Expression ◽  
Follow Up Study ◽  
All Cause Mortality ◽  
Mannan Binding Lectin ◽  
Binding Lectin

scholarly journals Mannan-Binding Lectin in Diabetic Kidney Disease: The Impact of Mouse Genetics in a Type 1 Diabetes Model

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Jakob Appel Østergaard ◽  
Mette Bjerre ◽  
Satish Posettihalli RamachandraRao ◽  
Kumar Sharma ◽  
Jens Randel Nyengaard ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Nephropathy ◽  
Kidney Disease ◽  
Genetic Background ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Mannan Binding Lectin ◽  
The Impact ◽  
Binding Lectin

Background. Mannan-binding lectin (MBL) is involved in the development of diabetic nephropathy. MBL is a part of the innate immune system where it can activate the complement system. Serum MBL level predicts later renal impairment in diabetes patients. Direct involvement of MBL in the development of diabetic kidney disease is observed in one animal strain. However, this involvement may differ among the animal strains. We thus examined the impact of the genetic background on the role of MBL in diabetic nephropathy.Materials/Methods. C57BL/6JBomTac and 129S6/SvEvTac mice were compared. In both strains, experimental type 1 diabetes was induced in wild-type (WT) and MBL-knockout (MBL-KO) mice by streptozotocin. Nondiabetic WT and MBL-KO mice were used as controls. We tested if MBL modified the diabetes-induced kidney changes by two-way ANOVA allowing for interaction.Results. MBL aggravated diabetes-induced kidney growth and glomerulus enlargement in C57BL/6JBomTac mice. MBL did not modify diabetes effects on glomerular basement membrane thickness or mesangial volume in any strain. Diabetes-induced changes in renal gene transcription of growth factors and matrix components were unaffected by MBL.Conclusions. Strain-specific MBL effects were found on downstream diabetic kidney changes. This emphasizes the importance of genetic background in this model of diabetic complications.

scholarly journals TLR9-Deficiency in B Cells Promotes Immune Tolerance via IL-10 in a Type 1 Diabetes Mouse Model

Diabetes ◽  
2020 ◽  
pp. db200373
Author(s):  
Sha Sha ◽  
James A Pearson ◽  
Jian Peng ◽  
Youjia Hu ◽  
Juan Huang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
B Cells ◽  
Mouse Model ◽  
Immune Tolerance ◽  
Diabetes Mouse
Sign in / Sign up

Export Citation Format

Share Document